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Abstract: Body fluids of patients with head and neck squamous cell carcinoma (HNSCC) are enriched
in exosomes that reflect properties of the tumor. The aim of this study was to determine whether
purine metabolites are carried by exosomes and evaluate their role as potential contributors to tumor
immune escape. The gene expression levels of the purine synthesis pathway were studied using
the Cancer Genome Atlas (TCGA) Head and Neck Cancer database. Exosomes were isolated from
supernatants of UMSCC47 cells and from the plasma of HNSCC patients (n = 26) or normal donors
(NDs; n = 5) using size exclusion chromatography. Ultraperformance liquid chromatography–tandem
mass spectrometry (UPLC-MS/MS) was used to assess levels of 19 purine metabolites carried by
exosomes. In HNSCC tissues, expression levels of genes involved in the purinergic pathway were
upregulated indicating an accelerated purine metabolism compared to normal tissues. Exosomes
from supernatants of UMSCC47 cells contained several purine metabolites, predominantly adenosine
and inosine. Purine metabolite levels were enriched in exosomes isolated from the plasma of
HNSCC patients compared to those isolated from NDs and carried elevated levels of adenosine
(p = 0.0223). Exosomes of patients with early-stage disease and no lymph node metastasis contained
significantly elevated levels of adenosine and 5′-GMP (p = 0.0247 and p = 0.0229, respectively).
The purine metabolite levels in exosomes decreased in patients with advanced cancer and nodal
involvement. This report provides the first evidence that HNSCC cells shuttle purine metabolites
in exosomes, with immunosuppressive adenosine being the most prominent purine. Changes
in the content and levels of purine metabolites in circulating exosomes reflect disease progression
in HNSCC patients.
Keywords: exosomes; extracellular vesicles; TEX; HNSCC; head and neck cancer; purine metabolites;
adenosine; purinergic signaling
1. Introduction
Head and neck squamous cell carcinomas (HNSCC) account for about 40,000 new cases per
year in the United States and more than 600,000 cases annually worldwide [1]. Only 40–50% of
patients with HNSCC will survive for five years and this is in part a result of the different etiologies
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and the heterogeneity of molecular changes that drive carcinogenesis of HNSCC [1,2]. Most epithelial
malignancies, including HNSCC, are characterized by overexpression of oncogenes, growth factor
receptors, enzymes and various immunosuppressive factors inhibiting functions of immune cells [2,3].
One important mechanism facilitating tumor escape from immune surveillance is the signaling
via purine nucleotides and nucleosides, such as adenosine and adenosine 5′-triphosphate (ATP) [4].
Purinergic signaling plays a key role in modulating immune responses in physiological and pathological
conditions. Physiologically, anti-inflammatory effects of adenosine balance proinflammatory ATP,
protecting tissues from damage caused by activated immune cells. Pathologically, increased adenosine
monophosphatase (AMPase) activity in tumors leads to increased adenosine production, generating a
deeply immunosuppressed tumor microenvironment (TME) and promoting cancer progression [5].
Most recently, tumor-derived exosomes (TEX) have been recognized as one of the key
immunosuppressive mechanisms operating in the TME [6]. These virus-size (30–150 nm) extracellular
vesicles (EVs) are mediators of intercellular communication and serve as the transport system for a
variety of molecules and factors shuttled between the tumor and immune cells locally in the TME and at
distant sites [7]. The composition of TEX cargos is complex and includes the cell membrane-derived
as well as cytosolic components of the producer tumor cell, including a broad variety of proteins, lipids
and nucleic acids [8]. Surface-bound ligands on TEX are competent in inducing signaling-cascades
in recipient cells, which leads to functional reprogramming of cells in the TME and promotes
the formation of the immunosuppressive tumor-associated immune system [9]. Besides surface
interactions, TEX are internalized by recipient cells, delivering nucleic acids and initiating the generation
of new functional proteins [10]. Recent evidence suggests that TEX may interact with recipient
cells via purinergic signaling pathways [11]. Specifically, our group has previously shown that
HNSCC-derived exosomes carry components of the adenosine pathway, including the ectonucleotidases
CD39 and CD73 [11,12]. These enzymes were functionally-active, as measured by exosome-mediated
hydrolysis of exogenous (e)ATP to adenosine, and were present in exosomes isolated from the plasma
of normal donors (ND) or HNSCC patients [12]. Additional analysis indicated that exosomes obtained
from the plasma of HNSCC patients had higher levels of ectonucleotidases than exosomes isolated
from the plasma of NDs [12]. Additionally, Clayton et al. [13] reported that 5′-AMP converted to
adenosine by CD39+/CD73+ TEX inhibited T cell activation via the adenosine A2AR independently of
CD73 expression on T cells.
While the presence of ectonucleotidases on the exosome surface has been well documented, little
is known about the presence of other components of the purinergic signaling pathway in the exosome
cargo. Sayner et al. [14] reported that exosomes derived from pulmonary microvascular endothelial
cells as well as exosomes collected from the perfusate of isolated rat lungs contained cAMP that
mediated cellular signaling. Our recently published data indicated that TEX produced by an HNSCC
cell line contained adenosine and inosine and induced adenosine A2BR-mediated responses in recipient
endothelial cells [11]. These data suggested that exosomes released by tumor cells might encapsulate
various components of the purinergic pathway. To further investigate the presence and role of
purine metabolites in HNSCC-derived exosomes, we screened exosomes isolated from supernatants of
HNSCC cell lines and from the plasma of HNSCC patients for a range of purine metabolites by mass
spectrometry. We found that TEX were enriched in purine metabolites and that a correlation between
levels of these metabolites in TEX and clinicopathological endpoints in HNSCC patients could have
clinical significance.
2. Materials and Methods
2.1. The Cancer Genome Atlas (TCGA) Analysis
The TCGA Head and Neck Cancer database was analyzed using the University of California, Santa
Cruz (UCSC) Xena Browser [15]. In total, 520 cases of primary HNSCC were included in this study.
Tumors were resected from different locations across the patients’ heads and necks and represented
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stage I to IV tumors. Data was compared to 44 “solid tissue normals” which are taken from normal
tissues near the tumor. Gene expression data of defined gene sets were generated and clustered online,
and the data were downloaded for subsequent statistical analysis.
2.2. Cell Lines
The HPV(−) cell lines PCI-13 and PCI-30 derived from human HNSCC were established
and maintained in our laboratory [16] and the HPV(+) cell lines UMSCC2, UMSCC47 and UMSCC90
were established by Dr. Thomas Carey (University of Michigan, Ann Arbor, MI, USA) and obtained
from Robert L. Ferris (UPMC Hillman Cancer Center, Pittsburgh, PA, USA). Given the equivalent
exosome sample purity and comparable results within the cell lines, UMSCC47 cells are presented
as a representative line [17]. The detailed characteristics of TEX deriving from HPV(+) or HPV(−)
HNSCC cell lines were previously described by us in detail [18,19]. Cells were authenticated
prior to their use and were grown in DMEM (Lonza Inc., Basel, Switzerland) supplemented with
1% (v/v) penicillin/streptomycin and 10% (v/v) FBS (Gibco, Thermo Fisher Scientific) at 37 ◦C
and in the atmosphere of 5% CO2 in air. FBS was depleted of exosomes by ultracentrifugation
at 100,000× g for 3 h. For exosome isolation, 2.5 × 106 UMSCC47 cells were seeded with 25 mL media
in 150 cm2 cell culture flasks as previously described [17]. Supernatants were collected after 72 h.
2.3. Patients
Peripheral venous blood specimens were collected from 26 patients with HNSCC with active
disease (AD) seen at the UPMC Otolaryngology Clinic in 2016–2019. Blood specimens from 5 normal
donors (NDs) served as controls. Informed consent from all individuals was obtained, and the study
was approved by the institutional review board of the University of Pittsburgh (UPCI 09-069/IRB991206,
annually approved, last date of approval: 7 April 2020). The blood samples were delivered to
the laboratory and were centrifuged at 1000× g for 10 min to separate the plasma from blood
components. Plasma was stored in 2 mL aliquots at −80 ◦C and thawed just prior exosome isolation.
2.4. Exosome Isolation by mini-SEC
The processing of supernatants and exosome isolation by mini-SEC was performed as previously
described in detail [20]. Briefly, cell culture supernatants were centrifuged at room temperature
(RT) for 10 min at 2000× g, transferred to new tubes for centrifugation at 10,000× g at 4 ◦C for
30 min and filtrated using a 0.22 µm bacterial filter. Afterwards, aliquots of supernatants were
concentrated by using Vivacell 100 concentrators (Sartorius, Göttingen, Germany) at 2000× g. 1 mL of
concentrated supernatant was loaded on a 10 cm-long Sepharose 2-B column (Bio-Rad, Hercules, CA,
USA) and individual 1 mL fractions were collected. Fraction #4 containing nonaggregated exosomes
was used in subsequent assays.
For isolation of exosomes from patients’ or NDs’ plasma, cryopreserved samples were thawed,
centrifuged at RT for 10 min at 2000× g, transferred to new tubes for centrifugation at 10,000× g at
4 ◦C for 30 min and filtrated using a 0.22 µm bacterial filter. Afterwards, 1 mL of precleared plasma
samples were loaded on individual Sepharose 2-B columns as previously described [20].
2.5. Exosome Characterization
Determination of protein concentrations by BCA, transmission electron microscopy (TEM)
and Western blotting of isolated exosomes was performed as previously described [20]. Size distribution
and concentrations of the particles were analyzed using tunable-resistive pulse sensing (TRPS) by
qNano (Izon, Medford, MA, USA) as described previously [21]. The methodology was optimized
according to current MISEV2018 guidelines from the International Society for Extracellular Vesicles [22].
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2.6. UPLC-MS/MS for Purine Metabolites
Hundred µg of exosomes in PBS were mixed with internal standards and injected onto a Waters
(Milford, MA, USA) Acquity ultraperformance liquid chromatograph (UPLC) connected to a Waters
UPLC BEH C18 column (1.7 µm beads; 2.1 × 150 mm). Purines were quantified by selected reaction
monitoring using a triple quadrupole mass spectrometer (TSQ Quantum-Ultra; Thermo Fisher Scientific,
San Jose, CA, USA) with a heated electrospray ionization source. The mobile phase was a linear
gradient flow rate (300 µL/min) of 1% acetic acid in water (pH, 3; mobile phase A) and 100% methanol
(mobile phase B). The gradient (A/B) settings were: from 0 to 2 min, 99.6%/0.4%; from 2 to 3 min,
to 98.0%/2.0%; from 3 to 4 min, to 85.0%/15.0%; from 4 to 6.5 min, to 99.6%/0.4%. The instrument
parameters were: sample tray temperature, 10 ◦C; column temperature, 50 ◦C; ion spray voltage,
4.0 kilovolts; ion transfer tube temperature, 350 ◦C; source vaporization temperature, 320 ◦C; Q2 CID
gas, argon at 1.5 mTorr; sheath gas, nitrogen at 60 psi; auxiliary gas, nitrogen at 35 psi; Q1/Q3 width,
0.7/0.7 units full-width half-maximum; scan width, 0.6 units; scan time, 0.01 s. The mass transitions,
collision energies and retention times for the measured purines and their corresponding internal
standards are provided in Tables 1 and 2.
Table 1. Adenine panel.
Internal Standard or Target Purine Parent Ion (m/z) Collision Energy (volts) Daughter Ion (m/z) Approximate Retention Time (min)
Analysis of Adenosine
13C10-Adenosine 278 19 141 3.29
Adenosine 268 19 136 3.29
Analysis of 3′,5′-cAMP
13C5-3′,5′-cAMP 335 28 136 3.8
3′,5′-cAMP 330 28 136 3.8
Analysis of 2′,3′-cAMP
13C5-2′,3′-cAMP 335 28 136 2.42
2′,3′-cAMP 330 28 136 2.42
Analysis of 5′-AMP
13C10-5′-AMP 358 19 141 1.72
5′-AMP 348 19 136 1.72
Analysis of 3′-AMP
13C5-3′-AMP 353 19 136 2.16
3′-AMP 348 19 136 2.16
Analysis of 2′-AMP
13C5-2′-AMP 353 19 136 3.10
2′-AMP 348 19 136 3.10
Analysis of Inosine
15N4-Inosine 273 20 141 3.10
Inosine 269 20 137 3.10
Analysis of Hypoxanthine
13C5-Hypoxanthine 141.8 22 124 1.86
Hypoxanthine 136.8 22 119 1.86
Analysis of Xanthine
15N2-Xanthine 154.9 20 137.8 2.00
Xanthine 152.9 20 135.8 2.00
Analysis of Adenine
13C515N5-Adenine 146 21 128 1.50
Adenine 136 21 119 1.50
Table 2. Guanine Panel.
Internal Standard or Target Purine Parent Ion (m/z) Collision Energy (volts) Daughter Ion (m/z) Approximate Retention Time (min)
Analysis of Guanosine
13C10,15N5-Guanosine 299 20 162 3.10
Guanosine 284 20 152 3.10
Analysis of 3′,5′-cGMP
13C5-3′,5′-cGMP 351 16 152 4.28
3′,5′-cGMP 346 16 152 4.28
Analysis of 2′,3′-cGMP
13C5-3′,5′-cGMP 351 152 4.28
2′,3′-cGMP 346 16 152 2.96
Analysis of 5′-GMP
13C10-5′-GMP 374 15 157 1.76
5′-GMP 364 15 152 1.76
Analysis of 3′-GMP
13C10-5′-GMP 374 15 157 1.76
3′-GMP 364 15 152 2.43
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Table 2. Cont.
Internal Standard or Target Purine Parent Ion (m/z) Collision Energy (volts) Daughter Ion (m/z) Approximate Retention Time (min)
Analysis of 2′-GMP
13C10-5′-GMP 374 15 157 1.76
2′-GMP 364 15 152 3.80
Analysis of Guanine
13C2,15N-Guanine 155 20 138 1.56
Guanine 152 20 135 1.56
Analysis of 8-Aminoguanosine
13C2,15N-8-Aminoguanosine 302 17 170 3.64
8-Aminoguanosine 299 17 167 3.64
Analysis of 8-Aminoguanine
13C2,15N-8-Aminoguanine 170 18 153 1.50
8-Aminoguanine 167 18 150 1.50
2.7. Statistical Analysis
All data were analyzed using the GraphPad Prism software (v7.0). Values are expressed
as mean ± SEM. Differences between groups were assessed by Student t test and differences were
considered significant at p < 0.05.
3. Results
3.1. mRNA Transcripts for Purine Metabolites Are Upregulated in HNSCC
To characterize the impact of purine metabolism in HNSCC, the gene expression levels of a
selected panel of mRNAs involved in purine synthesis were analyzed using the TCGA database.
The associations between purine metabolites are presented in Figure 1B. Gene expression levels
in 520 cases of HNSCC were compared to the expression levels in 44 samples of nonmalignant solid
tissue. The analysis revealed that most genes involved in the metabolism of purines were elevated
in expression in HNSCC compared to normal tissues. In particular, levels for ADA, ENTPD1, HPRT1,
NME1, NT5E, PNP, PPAT and PRPS1 were all significantly elevated in HNSCC tissues (p < 0.0001;
Figure 1). In contrast, there was a significant downregulation of CMPK1 and CNP in HNSCC tissue
compared to normal controls (p < 0.05; Figure 1A). No statistical differences were observed for ADK,
APRT and XDH.Cancers 2020, 12, x 6 of 15 
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Figure 1. Analysis of gene expression levels of individual purine synthesis pathway
mRNAs in the Cancer Genome Atlas (TCGA) database for head and neck squamous cell carcinoma
(HNSCC) using the University of California, Santa Cruz Xena Browser. (A) Gene expression levels
in 520 cases of primary HNSCC were compared to 44 solid normal tissues. Box and whiskers
plot showing median, range of 25–75% and the minimum–maximum values. * p < 0.05. (B) A
schema showing associations between purine metabolites. Numbers correspond to x-axis labels in (A)
and indicate functions of enzymes that were analyzed using the TCGA database.
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These data indicate that HNSCC tissues require and utilize higher purine levels, and that
this demand for purines is met by the upregulation of the purine metabolism in cancer cells.
We hypothesized that as a consequence of the higher production of purine metabolites in tumor
cells, exosomes produced by these cells are also likely to be enriched in various purines.
3.2. TEX Produced by HNSCC Cells Encapsulate Purine Metabolites
To analyze the cargo composition of TEX, supernatants of HNSCC cell lines, including UMSCC47,
were initially used to isolate TEX. All EVs isolated by SEC from the tumor cell line supernatants are
TEX. As previously described by us, the isolated small EVs in Fraction #4 meet the criteria established
for exosomes regardless of HPV status of primary cells [18,20]. Specifically, Western blots of TEX show
the presence of the exosome marker TSG101, as well as the absence of the negative marker Grp94
(Figure 2C). Particle sizes ranged from 80 to 150 nm as analyzed by qNano (Figure 2B) and Fraction #4
exosomes showed the typical size and vesicular morphology as visualized by TEM (Figure 2A).Cancers 2020, 12, x 7 of 15 
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3.3. Exosomes Derived from HNSCC Patients’ Plasma Contain Purine Metabolites
The clinicopathological data of the patients who were included in this study are listed in Table 3.
In this predominantly male (69%) patient cohort, the average patient’s age was 64.2 years, representing
a typical HNSCC patient population. Most tumors were located in the oral cavity (69%) followed by
tumors in the larynx and pharynx. Most patients had small tumors (T1 or T2; 23% each) and 58%
of the patients had negative lymph nodes (LNs). No patient had distant metastases at the time
of diagnosis. Approximately half of the patients consumed alcohol (46%) and the majority (69%)
consumed tobacco.
Table 3. Clinicopathological characteristics of the HNSCC patients included in this study.
Characteristics





Age at diagnosis (y)
Average ± SD 64.2 ± 13.27
Range 39–99
Primary tumor site
Larynx and pharynx 8 31
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Table 3. Cont.
Characteristics
















The exosomes isolated from HNSCC plasma were a mix of vesicles potentially derived from
various cell types: TEX represented a variable proportion of these exosomes as we previously
reported [6]. In comparison with HNSCC cell-line-derived TEX, exosomes isolated from the plasma of
HNSCC patients carried a broader spectrum of purine metabolites (Figure 3B), which is not surprising
due to the heterogeneous cellular origins of exosomes circulating in plasma. Most importantly,
high levels of adenosine, inosine, hypoxanthine and xanthine (0.4–1.0 ng/100 µg of TEP) were detected
in plasma-derived exosomes from HNSCC patients (Figure 3B). Compared to UMSCC47 cell-derived
exosomes, plasma-derived exosomes showed elevated values of 2′-AMP, 3′-AMP and 5′-AMP.
In addition, plasma-derived exosomes carried 3′,5′-cGMP, 2′-GMP, 3′-GMP, 5′-GMP, guanosine
and guanine which were only present in low levels in TEX from UMSCC47 (Figure 3A,B).
3.4. Levels of Purine Metabolites are Upregulated in Plasma-Derived Exosomes from Cancer Patients Compared
to Normal Donors
To determine the potential clinical significance of purine metabolite levels in plasma-derived
exosomes in HNSCC, we compared exosome samples from patients (n = 26) with those obtained
from the plasma of NDs (n = 5). First, TEP values were quantified and showed a significant increase
in circulating exosomes in HNSCC patients compared to ND (p = 0.0268; Figure 4A). Next, purine
metabolite levels were normalized to 100 µg TEP. Importantly, the means of almost all the purine
metabolites in the panel were higher in exosomes of HNSCC patients compared to NDs (Figure 4B).
Only adenine and guanine were present at similar levels in HNSCC patients and NDs. However,
due to the small group numbers and a wide spread of the data in HNSCC patients, the increase for
most purine metabolites was not statistically significant. Only adenosine was significantly enriched
in plasma-derived exosomes from HNSCC patients compared to those isolated from the plasma of NDs
(p = 0.0223). The individual values for adenosine in exosomes isolated from the plasma of HNSCC
patients or NDs are presented in Figure 4C.
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3.5. Purine Metabolite Levels in Plasma-Derived Exosomes are Elevated in Patients with Early-Stage Tumors
Next, the levels of purine metabolites in the panel of plasma-derived exosomes from HNSCC
patients were correlated with the available clinicopathologic data. Using the tumor extension as a
metric and triaging patient based on their T status, we detected no statistically significant differences
in purine levels (Figure 5A). However, there was a trend for adenosine levels to decrease in exosomes
from patients with increasing tumor extensions (Figure 5B).
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Patients were then triaged based on their lymph node (LN) involvement status and purine
metabolite levels in exosomes. The exosome profiles in patients with (n = 10) and without (n = 15) LN
metastasis were compared. Interestingly, most purines in the panel showed higher values in patients
without LN metastasis, with only a few exceptions (inosine, 3′,5′-cGMP, guanosine, guanine; Figure 6A).
Levels of adenosine were significantly decreased in exosomes of patients with LN metastasis (p = 0.0247;
Figure 6B) as were the exosome levels of 5′-GMP (p = 0.0229; Figure 6C).Cancers 2020, 12, x 11 of 15 
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In aggregate, circulating exosomes of HNSCC patients with the early disease stage without LN
involvement contained high levels of purine metabolites. With the disease progression and appearance
of LN metastases, levels of purine metabolites in the panel decreased. Thus, changes in the purine
profile of exosomes emerge as potentially useful surrogates of disease progression.
4. Discussion
Exosomes and their role in tumor progression are of great current interest [11,21,23]. The molecular
cargo of exosomes is in part derived from the surface of parent cells and also from endosomes, providing
exosomes with a molecular signature that resembles that of tumor cells [24]. The most frequently
described cargo components of exosomes are proteins, nucleic acids and lipids [8]. Metabolites, which
are also a part of the exosomal cargo, have received relatively little attention [25]. Studies based on
different LC-MS approaches revealed that the metabolome of exosomes contained fatty acids and amino
acids, steroid , prenols and eicosanoi s, peptides and peptide conjugat s, nucleotides, nucleosid s
and heir derivatives, as well as less abundant sugars, alcohols, amino acids and carboxylic acids [26,27].
The knowledg of m tabolite that are enriched in exosomes could be used to gain novel nsigh s into
the role of xo omes as a noninvasive liquid biopsy or as potential disease biomarkers [27].
In this study, we provided evidence that HNSCC cells have a generally accelerated purine
metabolism and that exosomes from HNSCC encapsulate a broad spectrum f urine metabolites,
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including adenosine and its derivatives. This is a significant finding, since the stability of these
metabolites as soluble circulating factors is limited. Their encapsulation into exosomes could serve as a
protection against catabolism or uptake by cells. Encapsulation of purine metabolites into exosomes
may also represent a mechanism for their dissemination and an opportunity to act as circulating, rather
than strictly local, factors. The functional relevance of such encapsulation of purines into exosomes
has been previously discussed. For example, it has been suggested that exosomes might provide
an additional compartment for cAMP signaling [14]. Additionally, adenosine-rich exosomes were
previously shown to promote adenosine A2BR-mediated angiogenesis [11]. In this study, adenosine
is shown to be a prominent component of the exosome purine panel in HNSCC. Adenosine levels
in exosomes of HNSCC patients were higher than those in ND’s exosomes, suggesting that tumor
cells export adenosine via exosomes and utilize this mechanism to enhance autocrine protumor effects.
Adenosine is an immunosuppressive and proangiogenic factor, which has a strong impact on cancer
progression [5,11,13]. Adenosine byproducts, including, e.g., inosine or hypoxanthine, also have
immunoregulatory activity [28]. We and others have suggested that tumor-induced dysfunction of
immune cells, a common finding in HNSCC patients, is largely mediated by circulating exosomes
capable of reprogramming the TME and promoting protumor activities [29]. Our experimental
approach did not include the separation of TEX from non-TEX and, therefore, it is currently not clear
whether purine metabolites are mainly enriched in TEX or in exosomes derived from other cell types.
However, our main finding, that adenosine is the most relevant purine encapsulated in plasma-derived
exosomes from HNSCC patients corresponded with our cell line-based results with pure TEX isolated
from HNSCC cell lines. Additionally, we and others have reported that in patients with cancer,
including HNSCC, exosome plasma levels are significantly increased relative to ND plasma [21,30].
The determination of the proportion of TEX to non-TEX in the plasma of cancer patients is a subject of
ongoing research; however, based on our recent findings, TEX levels are correspondingly but variably
high in patients’ plasma, and they are a major fraction of total plasma exosomes in patients with
advanced disease [6]. In HNSCC, we previously showed that the suppression of lymphocyte functions
by plasma-derived exosomes correlates with disease activity in patients, even without any separation
of TEX and non-TEX [31].
While adenosine was the most highly and consistently enriched metabolite in TEX from tumor cell
lines as well as plasma-derived exosomes in HNSCC patients, also the other purines present in the panel,
including cAMP and AMP, can be readily metabolized to adenosine, increasing the total adenosine
content. Additionally, noncanonical cyclic nucleotides, such as 2′,3′-cAMP were described as a source
for adenosine, since extracellular 2′,3′-cAMP is metabolized to 2′-AMP and 3′-AMP, which in turn
are metabolized to adenosine [32]. Similar observations were made for 2′,3′-cGMP and guanosine
which were shown to increase levels of extracellular adenosine [33,34]. In contrast, it was observed
that 3′,5′-cGMP, 2′,3′-cGMP, 2′,-GMP, 3′-GMP, 5′-GMP, and guanosine inhibit proliferation and induce
apoptosis of cancer cells, mediating antitumor effects [35]. Interestingly, the levels of metabolites
that mediate tumor progression in the adenosine panel were much higher compared to the levels of
metabolites that mediate antitumor effects in the guanine panel. This suggests that TEX are selectively
enriched in the cargo of metabolites that ultimately promotes tumor escape from immune surveillance
and accelerates disease progression.
Interestingly, quantification of purines in exosomes of HNSCC patients by UPLC-MS/MS indicated
that a cohort of patients with early disease without LN metastases had significantly elevated purine
levels in circulating exosomes. Surprisingly, exosomes of HNSCC patients with stage III/IV disease
and LN involvement had significantly lower purine content than that observed in the early disease
with N0. Whether this finding will be reproduced in studies of exosomes in a larger cohort of patients
remains to be seen, however, it might reflect an alteration in metabolic activity of parental tumor cells
in patients with more advanced metastatic activity and thus might prove to have clinical significance.
A lower content of purines in circulating exosomes could be an indication that purine metabolites
are mainly used for cellular maintenance and proliferation in metastatic tumor cells and thus fewer
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are packaged into exosomes and exported outside of the cell. It seems to indicate that the molecular
content of TEX and circulating exosomes is quantitatively and perhaps also qualitatively different
in metastatic than in primary cancers.
Currently, it remains unresolved whether accelerated packaging of purine metabolites into
exosomes in cancer is a mechanism used to eliminate an excess of “unwanted” metabolites to
sustain growth and survival of cancer cells. Alternatively, purine metabolites could be shuttled by
tumor cells into exosomes to mediate local and distant signaling, promoting tumor growth and inducing
suppression of immune cell functions. It is possible that both mechanisms are differentially used
by tumor cells, depending on the changing growth requirements during tumor progression. Future
studies will be necessary to evaluate whether the additional exosome-associated purine metabolites
present in exosomes, besides adenosine and cAMP, play a functional role in modulating protumor
responses in the TME.
Future studies are necessary to evaluate the purine metabolite content of exosomes deriving from
cells treated with inhibitors of the purine pathway, such as thiopurine drugs. Targeting the purine
pathway may emerge as an additional treatment option, also with regards to our recent findings that
targeting adenosine receptors impacts exosome production of cultured cells [36]. Future studies will
also be necessary to analyze purine metabolites in exosomes isolated from a larger patient cohort.
Ideally, these studies should be performed with matching plasma and tissue samples to evaluate
possible correlations of purine metabolite levels in exosomes with the expression of markers involved
in the purinergic signaling pathway in the primary tumor. Additionally, correlations of the immune
phenotype and exosome cargo would be of interest to evaluate the use of exosome-associated purine
metabolites as biomarkers of the immune system. These studies would serve as a basis for using
exosome metabolomics as a novel noninvasive and high-throughput tool to monitor HNSCC patients.
5. Conclusions
This report provides the first evidence that HNSCC cells shuttle purine metabolites in exosomes,
with immunosuppressive adenosine being the most prominent purine. Changes in the content
and levels of purine metabolites in circulating exosomes reflect disease progression in HNSCC patients.
Gaining insights into the biologic and molecular mechanisms that underlie exosome reprogramming
in the TME including immune suppression provides new opportunities for future translation of
exosome-based diagnostics or therapeutic interventions.
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